- Nachrichtendetail
-
26.04.2024 17:30:26 - dpa-AFX: EQS-News: RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting (english)
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General
Meeting
Relief Therapeutics Holding SA / Key word(s): AGMEGM
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General
Meeting
26.04.2024 / 17:30 CET/CEST
---------------------------------------------------------------------------
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General
Meeting of Shareholders Shareholders approved all proposals by a large
majority
GENEVA (APR. 26, 2024) - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB:
RLFTF, RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical
company committed to delivering innovative treatment options for select
specialty, unmet and rare diseases, announces the results of the
extraordinary general meeting (EGM) of shareholders, which took place in
Geneva today, Friday, April 26, 2024. The proposed resolutions were approved
by more than 85 percent of the represented votes.
EGM results
1. Election of new members of the Board of Directors
The EGM elected Mr. Peter de Svastich, Mr. Gregory Van Beek, and Mr. Thomas
Elzinga as new members of the Company's Board of Directors, for a term of
office extending until completion of the next Annual General Meeting
expected in June 2024. As anticipated, Ms. Patrice Jean and Mr. Thomas Plitz
have concluded their service on the Board of Directors, effective today.
Raghuram (Ram) Selvaraju, Chairman of the Board of Relief Therapeutics,
commented: "We are welcoming three new board members, each with valuable
expertise and fresh perspective, critical for guiding our strategic
direction and enhancing shareholder value. At the same time, we express our
deepest gratitude to our two departing members for their invaluable
contributions and dedication in shaping our path forward."
2. Capital Reduction by Reduction of Nominal Value
The EGM approved a reduction of the nominal value of the Company's share
capital from CHF 56'163'348.00 to CHF 1'404'083.70. The number of
outstanding shares, as well as shareholders' financial and patrimonial
rights, are not affected by this technical adjustment.
3. Increase of the Conditional Share Capital
The EGM approved an increase of the existing conditional share capital to
7'000'000 shares.
4. Reinstatement and Extension of the Capital Band
The EGM approved an increase of the Company's capital band to 7'000'000
shares and extended its duration until April 25, 2029.
The EGM approved a maximum amount of CHF 500'000 for compensation of the
members of the Board of Directors for the period from the Annual General
Meeting 2023 until the Annual General Meeting 2024, and a maximum amount of
CHF 4'000'000 for the members of the Executive Committee for the financial
year 2024, inclusive of fixed and variable compensation, stock options, and
other benefits.
6. Discharge of the Board of Directors and the Executive Committee
The EGM granted discharge to each and all members of the Board and of the
Executive Committee, including former members, for the financial years 2022
and 2023.
The EGM approved textual amendments to article 23 para. 1 and article 25
para. 3 of the Articles of Association for alignment with the new corporate
law.
The resolutions submitted for the shareholders' vote are detailed in the EGM
invitation. The detailed voting results will be made available on the
Company's website later today.
ABOUT RELIEF THERAPEUTICS
Relief Therapeutics is a commercial-stage biopharmaceutical company
committed to advancing treatment paradigms and delivering improvements in
efficacy, safety, and convenience to benefit the lives of patients living
with select specialty and rare diseases. Relief Therapeutics' portfolio
offers a balanced mix of marketed, revenue-generating products, our
proprietary, globally patented Physiomimic(TM) and TEHCLO(TM) platform
technologies and a targeted clinical development pipeline consisting of
risk-mitigated assets focused in three core therapeutic areas: rare skin
diseases, rare metabolic disorders, and rare respiratory diseases. In
addition, Relief Therapeutics is commercializing several legacy products via
licensing and distribution partners. Relief Therapeutics' mission is to
provide therapeutic relief to those suffering from rare diseases and is
being advanced by an international team of well-established, experienced
biopharma industry leaders with extensive research, development and rare
disease expertise. Relief Therapeutics is headquartered in Geneva, with
additional offices in Balerna, Switzerland, Offenbach am Main, Germany and
Monza, Italy. Relief Therapeutics is listed on the SIX Swiss Exchange under
the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and
RLFTY. For more information, please visit our website
www.relieftherapeutics.com or follow Relief Therapeutics on LinkedIn.
CONTACT:
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com
DISCLAIMER
This press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks, uncertainties, including its
ability to achieve its corporate, development and commercial goals, and
other factors which could cause the actual results, financial condition,
performance or achievements of Relief Therapeutics to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. A number of factors, including
those described in Relief Therapeutics' filings with the SIX Swiss Exchange
and the U.S. Securities and Exchange Commission (SEC), could adversely
affect Relief Therapeutics. Copies of Relief Therapeutics' filings with the
SEC are available on the SEC EDGAR database at www.sec.gov. Relief
Therapeutics does not undertake any obligation to update the information
contained herein, which speaks only as of this date.
---------------------------------------------------------------------------
Additional features:
File: https://eqs-cockpit.com/c/fncls.ssp?u=82e8603ba17651f529a6f5a4b2dce2f3
File description: Press Release_Relief_EGM Results
---------------------------------------------------------------------------
End of Media Release
---------------------------------------------------------------------------
End of News EQS News Service
---------------------------------------------------------------------------
1890737 26.04.2024 CET/CEST
Meeting
Relief Therapeutics Holding SA / Key word(s): AGMEGM
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General
Meeting
26.04.2024 / 17:30 CET/CEST
---------------------------------------------------------------------------
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General
Meeting of Shareholders Shareholders approved all proposals by a large
majority
GENEVA (APR. 26, 2024) - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB:
RLFTF, RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical
company committed to delivering innovative treatment options for select
specialty, unmet and rare diseases, announces the results of the
extraordinary general meeting (EGM) of shareholders, which took place in
Geneva today, Friday, April 26, 2024. The proposed resolutions were approved
by more than 85 percent of the represented votes.
EGM results
1. Election of new members of the Board of Directors
The EGM elected Mr. Peter de Svastich, Mr. Gregory Van Beek, and Mr. Thomas
Elzinga as new members of the Company's Board of Directors, for a term of
office extending until completion of the next Annual General Meeting
expected in June 2024. As anticipated, Ms. Patrice Jean and Mr. Thomas Plitz
have concluded their service on the Board of Directors, effective today.
Raghuram (Ram) Selvaraju, Chairman of the Board of Relief Therapeutics,
commented: "We are welcoming three new board members, each with valuable
expertise and fresh perspective, critical for guiding our strategic
direction and enhancing shareholder value. At the same time, we express our
deepest gratitude to our two departing members for their invaluable
contributions and dedication in shaping our path forward."
2. Capital Reduction by Reduction of Nominal Value
The EGM approved a reduction of the nominal value of the Company's share
capital from CHF 56'163'348.00 to CHF 1'404'083.70. The number of
outstanding shares, as well as shareholders' financial and patrimonial
rights, are not affected by this technical adjustment.
3. Increase of the Conditional Share Capital
The EGM approved an increase of the existing conditional share capital to
7'000'000 shares.
4. Reinstatement and Extension of the Capital Band
The EGM approved an increase of the Company's capital band to 7'000'000
shares and extended its duration until April 25, 2029.
5. Votes on the compensation of the members of the Board of Directors and
of the Executive Committee
The EGM approved a maximum amount of CHF 500'000 for compensation of the
members of the Board of Directors for the period from the Annual General
Meeting 2023 until the Annual General Meeting 2024, and a maximum amount of
CHF 4'000'000 for the members of the Executive Committee for the financial
year 2024, inclusive of fixed and variable compensation, stock options, and
other benefits.
6. Discharge of the Board of Directors and the Executive Committee
The EGM granted discharge to each and all members of the Board and of the
Executive Committee, including former members, for the financial years 2022
and 2023.
7. Amendments to the Articles of Association related to the New Corporate
Law
The EGM approved textual amendments to article 23 para. 1 and article 25
para. 3 of the Articles of Association for alignment with the new corporate
law.
The resolutions submitted for the shareholders' vote are detailed in the EGM
invitation. The detailed voting results will be made available on the
Company's website later today.
ABOUT RELIEF THERAPEUTICS
Relief Therapeutics is a commercial-stage biopharmaceutical company
committed to advancing treatment paradigms and delivering improvements in
efficacy, safety, and convenience to benefit the lives of patients living
with select specialty and rare diseases. Relief Therapeutics' portfolio
offers a balanced mix of marketed, revenue-generating products, our
proprietary, globally patented Physiomimic(TM) and TEHCLO(TM) platform
technologies and a targeted clinical development pipeline consisting of
risk-mitigated assets focused in three core therapeutic areas: rare skin
diseases, rare metabolic disorders, and rare respiratory diseases. In
addition, Relief Therapeutics is commercializing several legacy products via
licensing and distribution partners. Relief Therapeutics' mission is to
provide therapeutic relief to those suffering from rare diseases and is
being advanced by an international team of well-established, experienced
biopharma industry leaders with extensive research, development and rare
disease expertise. Relief Therapeutics is headquartered in Geneva, with
additional offices in Balerna, Switzerland, Offenbach am Main, Germany and
Monza, Italy. Relief Therapeutics is listed on the SIX Swiss Exchange under
the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and
RLFTY. For more information, please visit our website
www.relieftherapeutics.com or follow Relief Therapeutics on LinkedIn.
CONTACT:
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com
DISCLAIMER
This press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks, uncertainties, including its
ability to achieve its corporate, development and commercial goals, and
other factors which could cause the actual results, financial condition,
performance or achievements of Relief Therapeutics to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. A number of factors, including
those described in Relief Therapeutics' filings with the SIX Swiss Exchange
and the U.S. Securities and Exchange Commission (SEC), could adversely
affect Relief Therapeutics. Copies of Relief Therapeutics' filings with the
SEC are available on the SEC EDGAR database at www.sec.gov. Relief
Therapeutics does not undertake any obligation to update the information
contained herein, which speaks only as of this date.
---------------------------------------------------------------------------
Additional features:
File: https://eqs-cockpit.com/c/fncls.ssp?u=82e8603ba17651f529a6f5a4b2dce2f3
File description: Press Release_Relief_EGM Results
---------------------------------------------------------------------------
End of Media Release
---------------------------------------------------------------------------
Language: English
Company: Relief Therapeutics Holding SA
Avenue de Secheron 15
1202 Geneva
Switzerland
Phone: +41 22 545 11 16
E-mail: contact@relieftherapeutics.com
Internet: https://relieftherapeutics.com
ISIN: CH0100191136
Valor: 10019113
Listed: SIX Swiss Exchange
EQS News ID: 1890737
End of News EQS News Service
---------------------------------------------------------------------------
1890737 26.04.2024 CET/CEST
